Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $26,041.09 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Yeu Lin sold 379 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total value of $26,041.09. Following the completion of the sale, the insider directly owned 23,698 shares in the company, valued at approximately $1,628,289.58. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Thursday, March 19th, Elizabeth Yeu Lin sold 390 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $67.00, for a total value of $26,130.00.
• On Tuesday, March 17th, Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $69.42, for a total transaction of $26,032.50.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $64.51 on Friday. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25. The company’s 50-day moving average is $69.12 and its 200 day moving average is $70.30. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -39.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. Sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Finally, Barclays began coverage on Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $91.83.

Institutional Trading of Tarsus Pharmaceuticals

Several large investors have recently modified their holdings of the company. TimesSquare Capital Management LLC purchased a new position in Tarsus Pharmaceuticals in the third quarter worth about $15,898,000. Jennison Associates LLC increased its position in shares of Tarsus Pharmaceuticals by 5.5% during the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after purchasing an additional 136,582 shares during the last quarter. TFG Asset Management GP Ltd increased its position in shares of Tarsus Pharmaceuticals by 40.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock valued at $10,128,000 after purchasing an additional 71,530 shares during the last quarter. Capricorn Fund Managers Ltd bought a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $14,264,000. Finally, Jump Financial LLC lifted its stake in shares of Tarsus Pharmaceuticals by 385.9% in the 2nd quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock worth $9,606,000 after purchasing an additional 188,317 shares during the period. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.